<DOC>
	<DOCNO>NCT01756235</DOCNO>
	<brief_summary>The purpose study evaluate physical activity change participant rheumatoid arthritis ( RA ) treat adalimumab therapy clinical practice .</brief_summary>
	<brief_title>Physical Activity Patients With Rheumatoid Arthritis Treated With Adalimumab Routine Clinical Practice</brief_title>
	<detailed_description>This post-marketing observational study conduct multi-country , multi-center single-arm format . Data collect prospectively . Adult participant diagnosis RA assign treatment adalimumab ( Humira® ) eligible participation . During period four follow-up visit plan observation participant documentation data . Ideally , visit perform approximately 3 ( V1 ) , 6 ( V2 ) , 9 ( V3 ) 12 ( V4 ) month baseline visit ( V0 ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Had rheumatoid arthritis ( RA ) eligible start and/or continue adalimumab therapy accord local product label prescription guideline Had start adalimumab therapy one ( 1 ) month prior study enrolment Had negative result tuberculosis ( TB ) screen test receive TB prophylaxis per local guideline Had provide write Authorization investigator use and/or disclose personal and/or health data , Informed Consent request Local Regulations Was unable walk either due RA comorbid condition Was unable perform basic selfcare activity Had contraindication treatment adalimumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Post-marketing observational study ( PMOS ) Protocol</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Physical Activity</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Humira®</keyword>
</DOC>